Tumor lysis syndrome in a patient with metastatic, androgen independent prostate cancer
Article first published online: 18 NOV 2005
International Journal of Urology
Volume 12, Issue 11, pages 1012–1013, November 2005
How to Cite
WRIGHT, J. L., LIN, D. W., DEWAN, P. and MONTGOMERY, R. B. (2005), Tumor lysis syndrome in a patient with metastatic, androgen independent prostate cancer. International Journal of Urology, 12: 1012–1013. doi: 10.1111/j.1442-2042.2005.01196.x
- Issue published online: 18 NOV 2005
- Article first published online: 18 NOV 2005
- Received 1 November 2004; accepted 17 February 2005.
- hormone refractory;
- prostate cancer;
- tumor lysis syndrome
Abstract Tumor lysis syndrome (TLS) is an uncommon, but well described, clinical entity that typically occurs following chemotherapy in patients with rapidly growing hematological malignancies. It is rarely described in patients with solid tumors. We report a case of TLS in a patient with metastatic adenocarcinoma of the prostate after treatment with paclitaxel chemotherapy.